Search

To assess the objective and subjective image quality, and respiratory motion of hepatocellular carcinoma with portal vein tumor thrombosis (PVTT) using the contrast-enhanced four-dimensional dual-energy computed tomography (CE-4D-DECT). For twelve patients, the virtual monochromatic image (VMI) derived from the CE-4D-DECT with the highest contrast to noise ratio (CNR) was determined as the optimal VMI (O-VMI). To assess the objective and subjective image quality, the CNR and five-point score of the O-VMI were compared to those of the standard VMI at 77 keV (S-VMI). The respiratory motion of the PVTT and diaphragm was measured based on the exhale and inhale phase images. The VMI at 60 keV yielded the highest CNR (4.8 ± 1.4) which was significantly higher (p = 0.02) than that in the S-VMI (3.8 ± 1.2). The overall image quality (4.0 ± 0.6 vs 3.1 ± 0.5) and tumor conspicuity (3.8 ± 0.8 vs 2.8 ± 0.6) of the O-VMI determined by three radiation oncologists was significantly higher (p < 0.01) than that of the S-VMI. The diaphragm motion in the L-R (3.3 ± 2.5 vs 1.2 ± 1.1 mm), A-P (6.7 ± 4.0 vs 1.6 ± 1.3mm) and 3D (8.8 ± 3.5 vs 13.1 ± 4.9 mm) directions were significantly larger (p < 0.05) compared to the tumor motion. The improvement of objective and subjective image quality was achieved in the O-VMI. Because the respiratory motion of the diaphragm was larger than that of the PVTT, we need to be pay attention for localizing target in radiotherapy. [ABSTRACT FROM AUTHOR]

Virtual monochromatic images (VMIs) at a lower energy level can improve image quality but the computed tomography (CT) number of iodine contained in the contrast‐enhanced agent is dramatically increased. We assessed the effect of the use of contrast‐enhanced agent on the dose distributions in volumetric modulated arc therapy (VMAT) planning for head and neck cancer (HNC). Based on the VMIs at 40 keV (VMI40keV), 60 keV(VMI60keV), and 77 keV (VMI77keV) of a tissue characterization phantom, lookup tables (LUTs) were created. VMAT plans were generated for 15 HNC patients based on contrast‐enhanced‐ (CE‐) VMIs at 40‐, 60‐, and 77 keV using the corresponding LUTs, and the doses were recalculated based on the noncontrast‐enhanced‐ (nCE‐) VMIs. For all structures, the difference in CT numbers owing to the contrast‐enhanced agent was prominent as the energy level of the VMI decreased, and the mean differences in CT number between CE‐ and nCE‐VMI was the largest for the clinical target volume (CTV) (125.3, 55.9, and 33.1 HU for VMI40keV, VMI60keV, and VMI77keV, respectively). The mean difference of the dosimetric parameters (D99%, D50%, D1%, Dmean, and D0.1cc) for CTV and OARs was <1% in the treatment plans based on all VMIs. The maximum difference was observed for CTV in VMI40keV (2.4%), VMI60keV (1.9%), and VMI77keV (1.5%) plans. The effect of the contrast‐enhanced agent was larger in the VMAT plans based on the VMI at a lower energy level for HNC patients. This effect is not desirable in a treatment planning procedure. [ABSTRACT FROM AUTHOR]

Purpose: A contrast‐enhancing agent is imperative for the accurate target delineation of pancreatic tumors. This study demonstrates the potential use of treatment planning for patients with pancreatic tumors based on the water density image (WDI) generated by dual‐energy computed tomography (DECT). Methods: Tissue characterization and multi‐energy phantom scanning were performed through DECT and the physical characteristics of the WDI and a virtual monochromatic image (VMI) were assessed. The measured and the corresponding theoretical electron density relative to water (RED) and mass density (MD) were compared. Treatment plans based on the WDI (TPWDI) and VMI (TPVMI) were compared for 22 pancreatic cancer patients who underwent contrast‐enhanced DECT scan. Results: The total absolute difference in the HU value between the conventional 120 kVp images and the VMI was the smallest at the energy level of 77 keV (3.3 HU), and the VMI at 77 keV was used for subsequent analysis. The difference between the measured and theoretical values of RED and MD for iodine using the VMI (>15%) was larger than that using WDI (<4%). In clinical cases, the maximum difference in the dosimetric parameters between TPWDI and TPWDI for the planning target volume was 3.0% when the doses were calculated using AXB, and for the duodenum, it was 1.7%. Conclusions: The WDI estimated the RED and MD accurately and could form the basis for a new treatment planning approach for pancreatic cancer using contrast‐enhancing agent. [ABSTRACT FROM AUTHOR]

Purpose: To investigate whether a novel iterative cone-beam computed tomography (CBCT) reconstruction algorithm reduces metal artifacts in head and neck patient images.Method: An anthropomorphic phantom and 35 patients with dental metal prostheses or implants were analyzed. All CBCT images were acquired using a TrueBeam linear accelerator and reconstructed with a Feldkamp-Davis-Kress algorithm-based CBCT (FDK-CBCT) and an iterative CBCT algorithm. The mean Hounsfield unit (HU) and standard deviation values were measured on the tongue near the metal materials and the unaffected region as reference values. The artifact index (AI) was calculated. For objective image analysis, the HU value and AI were compared between FDK-CBCT and iterative CBCT images in phantom and clinical studies. Subjective image analyses of metal artifact scores and soft tissue visualizations were conducted using a five-point scale by two reviewers in the clinical study.Results: The HU value and AI showed significant artifact reduction for the iterative CBCT than for the FDK-CBCT images (phantom study: 389.8 vs.-10.3 for HU value, 322.9 vs. 96.2 for AI, FDK-CBCT vs. iterative CBCT, respectively; clinical study: 210.3 vs. 69.0 for HU value, 149.6 vs. 70.7 for AI). The subjective scores in the clinical patient study were improved in the iterative CBCT images (metal artifact score: 1.1 vs. 2.9, FDK-CBCT vs. iterative CBCT, respectively; soft tissue visualization: 1.8 vs. 3.6).Conclusions: The iterative CBCT reconstruction algorithm substantially reduced metal artifacts caused by dental metal prostheses and improved soft tissue visualization compared to FDK-CBCT in phantom and clinical studies. [ABSTRACT FROM AUTHOR]

Objective: Determination of the optimal energy level of virtual monochromatic image (VMI) for brain metastases in contrast-enhanced dual-energy CT (DECT) for radiosurgery and assessment of the subjective and objective image quality of VMI at the optimal energy level., Methods: 20 patients (total of 42 metastases) underwent contrast-enhanced DECT. Spectral image analysis of VMIs at energy levels ranging from 40 to 140 keV in 1 keV increments was performed to determine the optimal VMI (VMI opt ) as the one corresponding to the highest contrast-to-noise ratio (CNR) between brain parenchyma and the metastases. The objective and subjective values of VMI opt were compared to those of the VMI with 120 kVp equivalent, defined as reference VMI (VMI ref , 77 keV). The objective measurement parameters included mean HU value and SD of tumor and brain parenchyma, absolute lesion contrast (LC), and CNR. The subjective measurements included five-point scale assessment of "overall image quality" and "tumor delineation" by three radiation oncologists., Results: The VMI at 63 keV was defined as VMI opt . The LC and CNR of VMI opt were significantly ( p < 0.01) higher than those of VMI ref (LC: 37.4 HU vs 24.7 HU; CNR: 1.1 vs 0.8, respectively). Subjective analysis rated VMI opt significantly ( p < 0.01) superior to VMI ref with respect to the overall image quality (3.2 vs 2.9, respectively) and tumor delineation (3.5 vs 2.9, respectively)., Conclusion: The VMI at 63 keV derived from contrast-enhanced DECT yielded the highest CNR and improved the objective and subjective image quality for radiosurgery, compared to VMI ref ., Advances in Knowledge: This paper investigated for the first time the optimal energy level of VMI in DECT for brain metastases. The findings will lead to improvement in tumor visibility with optimal VMI and consequently supplement accuracy delineation of brain metastases.